- 专利标题： Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
-
申请号： US16770728申请日： 2018-12-14
-
公开(公告)号： US12071483B1公开(公告)日： 2024-08-27
- 发明人: Jinhyung Ahn , Sungwon An , Dongin Kim , Eunsil Sung , Jaehyun Eom , Sang Hoon Lee , Weonkyoo You , Juhee Kim , Kyungjin Park , Hyejin Chung , Jinwon Jung , Bora Lee , Byungje Sung , Yeunju Kim , Yong-Gyu Son , Seawon Ahn , Daehae Song , Jiseon Yoo , Youngdon Pak , Donghoon Yeom , Yoseob Lee , Jaeho Jung
- 申请人： ABL Bio Inc.
- 申请人地址： KR Seongnam-si
- 专利权人： ABL BIO INC.
- 当前专利权人： ABL BIO INC.
- 当前专利权人地址： KR Seongnam-si
- 代理机构： Steptoe LLP
- 代理商 Z. Ying Li; Wyan-Ching M. Lee
- 优先权： KR 20170172205 2017.12.14
- 国际申请： PCT/KR2018/015953 2018.12.14
- 国际公布： WO2019/117684A 2019.06.20
- 进入国家日期： 2020-06-08
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K47/68 ; C07K16/18 ; C07K16/28
摘要：
The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.
信息查询
